Disease relevance of Sporotrichosis

• Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group [1].
• Fluconazole has relatively poor efficacy against histoplasmosis, blastomycosis and sporotrichosis [2].
• We used itraconazole in the sequential treatment of six patients with systemic sporotrichosis: three with bone and joint disease and three with disseminated infection manifested by subcutaneous nodules [3].
• Disseminated cutaneous sporotrichosis in an AIDS patient receiving maintenance therapy with fluconazole for previous cryptococcal meningitis [4].
• Itraconazole was superior to fluconazole in candidosis, cryptococcosis, sporotrichosis and aspergillosis, and to amphotericin B and to flucytosine in candidosis, cryptococcosis and aspergillosis [5].

High impact information on Sporotrichosis

• Spook house sporotrichosis. A point-source outbreak of sporotrichosis associated with hay bale props in a Halloween haunted-house [6].
• We have shown in one patient with sporotrichosis of the knee that direct low-dose injections of amphotericin B can be performed safely, resulting in eradication of the fungus [7].
• Additionally, sera from humans with sporotrichosis contained antibodies that bound melanin particles [8].
• Four antifungal agents, amphotericin B, SDZ 89-485, itraconazole, and terbinafine, were tested for efficacy in a murine model of systemic sporotrichosis [9].
• Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide [10].

Chemical compound and disease context of Sporotrichosis

• PURPOSE: To describe the clinical presentation and outcomes of treatment with itraconazole in patients with sporotrichosis [1].
• Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole [11].
• Successful treatment of disseminated cutaneous sporotrichosis with ketoconazole [12].
• Treatment of cutaneous sporotrichosis with terbinafine [13].
• Disseminate cutaneous and osseous sporotrichosis is reported in a patient who failed to respond to 6 months of iodide therapy [14].

Anatomical context of Sporotrichosis

• This study was undertaken to examine the effects of immunization with Sporothrix schenckii and oral potassium iodide (KJ) administration on the chemiluminescence (CL) response of mouse polymorphonuclear leukocytes (PMNs) in experimental murine sporotrichosis [15].

Gene context of Sporotrichosis

• The involvement of interferon-gamma (IFN-gamma) and inducible nitric oxide synthase (iNOS) in the granuloma formation of sporotrichosis is less known [16].
• In contrast, the presence of Th2 response began in the 5th week, suggesting the participation of humoral immune response in advanced stages of sporotrichosis [17].
• We report a case of disseminated sporotrichosis in a 49-year-old man who was treated with multiple immunosuppressants, including tumor necrosis factor (TNF)-alpha antagonists (etanercept and infliximab), for presumed inflammation arthritis [18].
• A case of lymphocutaneous sporotrichosis that had developed from the dorsum nasi to the left buccal region of a 65-year-old woman was treated with itraconazole 100 mg day-1 [19].

Analytical, diagnostic and therapeutic context of Sporotrichosis

• No sera from 300 healthy individuals or 100 patients with various systemic mycoses other than sporotrichosis had ELISA titers greater than 64 [20].
• Successful chemotherapy of the systemic mycoses now covers a span of more than 75 years and dates to the first reported use of potassium iodide for treatment of sporotrichosis [21].
• The ultrastructural changes produced by iodine-potassium iodide solution on yeast cells of Sporothrix schenckii were investigated by transmission electron microscopy in order to clarify the mechanism of oral potassium iodide therapy for sporotrichosis [22].

References